Decline in circulating viral and human tumor markers after resection of head and neck carcinoma. Issue 1 (28th August 2020)

• Record Type: Journal Article
• Authors: Lopez, Erin M.; Tanner, April Michelle; Du, Eugenie; Patel, Samip N.; Weiss, Jared; Weissler, Mark C.; Hackman, Trevor; Gupta, Gaorav P.; Zevallos, Jose; Elmore, Sandra; Betancourt, Renee; Thorne, Leigh; Sheth, Siddharth; Gulley, Margaret L.
• Is Part Of: Head & neck. Volume 43:Issue 1(2021)
• Page Start: 27
• Page End: 34
• Publication Date: 2020-08-28
• Subjects: carcinoma -- cell‐free DNA -- DNA sequencing -- human papillomavirus -- tumor markers; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.26444
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: DNA sequencing panels can simultaneously quantify human and viral tumor markers in blood. We explored changes in levels of plasma tumor markers following surgical resection of head and neck carcinoma. Methods: In preresection and postresection plasmas, targeted DNA sequencing quantified variants in 28 human cancer genes and levels of oncogenic pathogens (human papillomavirus [HPV], Epstein‐Barr virus [EBV], Helicobacter pylori ) from 21 patients with head and neck squamous cell carcinoma. Results: Preresection, 11 of 21 patients (52%) had detectable tumor markers in plasma, most commonly TP53 mutation or HPV genome. Several days postresection, levels fell to undetectable in 8 of 10 evaluable patients, while two high‐stage patients retained circulating tumor markers. Conclusions: Modern sequencing technology can simultaneously quantify human gene variants and oncogenic viral genomes in plasma. Falling levels of cancer‐specific markers upon resection can help identify viral and human markers to track at subsequent timepoints as a means to evaluate efficacy of interventions.